Regioselective side-chain as well as nuclear monobromination of aromatic substrates with N-bromosuccinimide using phosphotungstic acid supported on zirconia as a heterogeneous catalyst

Regioselective monobromination of aromatic substrates with N-bromosuccinimide has been achieved in excellent isolated yields (84–98%) using phosphotungstic acid supported on zirconia as a novel heterogeneous catalyst. The catalyst has been characterized by means of X-ray diffraction (XRD), scanning electron microscopy (SEM), surface area and acidity measurements. Remarkably, the new catalyst system described brought about the side-chain bromination of aromatics to afford bromomethyl arenes in excellent yields (86–98%) without the need for a radical initiator. Recovery and recylability of the catalyst have been well established.     

Additives for the reduction of sulfur in FCC gasoline

Sulfur reduction ability of alumina supported zinc, gallium and zinc-gallium additives for fluid catalytic cracking catalysts was evaluated in a micro-activity test unit (MAT). Gallium/alumina showed the highest sulfur reduction of 31%, but the cracking activity of the catalyst was decreased. Zinc-gallium/alumina reduced sulfur in 24 wt.% without decreasing the base catalyst activity.     

Synthesis and biological activities of tetrahydroquinazoline analogs of aminopterin and methotrexate

(6R,6S)-5,8-Dideaza-5,6,7,8-tetrahydroaminopterin ( 1 ) and (6R,6S)-5,8-dideaza-5,6,7,8-tetrahydromethotrexate ( 2 ) were synthesized as potential inhibitors of dihydrofolate reductase (DHFR) and as antitumor agents. Cyclohexanone-4-carboxaldehyde dimethyl acetal, a key intermediate [10] was synthesized from cyclohexane-1,4-dione monoethylene ketal, which was converted via a Wittig reaction to its exocyclic 4-methylene derivative which in turn, was converted to the 4-aldehyde via a hydroboration-oxidation sequence. Selective protection of the 4-aldehyde as the dimethylacetal and cyclization with dicyandiamide afforded the 6-dimethylacetal of 2,4-diamino-5,6,7,8-tetrahydroquinazoline. Protection of the 2,4-diamino moieties and selective deprotection of the 6-aldehyde followed by reductive amination with p-aminobenzoyl-L-glutamate afforded 2,4-bisacetamido-5,8-dideaza-5,6,7,8-tetrahydroaminopterin ( 11 ). Deprotection of 11 afforded 1 . Compound 2 was obtained from 11 via N¹⁰-methylation and deprotection. The N¹⁰-methyl analogue 2 was 2–10 fold more potent than 1 as an inhibitor of various DHFRs. In the in vitro preclinical screening program of the National Cancer Institute, compound 2 inhibited the growth of eighteen of the twenty nine tumor cell lines in culture at a GI₅₀ > 1.0 × 10^?8 M.     

Development and Validation of Kinetic Spectrophotometric Method for the Determination of Losartan Potassium in Pure and Commercial Tablets

A validated kinetic spectrophotometric method has been developed for the determination of losartan potassium in pure and dosage forms. The method is based on oxidation of the losartan potassium with alkaline potassium permanganate at room temperature (25 ± 1 °C). The reaction is followed spectrophotometrically by measuring the increase in absorbance with time at 603 nm, and the initial rate, fixed time (at 12.0 min) and equilibrium time (at 90.0 min) methods are adopted for constructing the calibration graphs. All the calibration graphs are linear in the concentration range of 7.5–60.0 μg mL^?1 and the calibration data resulted in the linear regression equations of n? = ?6.422 × 10^?7 + 1.173 × 10^?5 C, A =3.30 × 10^?4 + 5.28 × 10^?3 C and A = ?2.09 × 10^?2 + 1.05 × 10^?1 C for initial‐rate, fixed time and equilibrium time methods, respectively. The limits of detection for initial rate, fixed time and equilibrium time methods are 0.71, 0.21 and 0.19 μg mL^?1, respectively. The activation parameters such as E_a, ΔH^?, ΔS^?, and ΔG^? are also determined for the reaction and found to be 87.34 KJ mol^?1, 84.86 KJ mol^?1, 50.96 JK^?1 mol^?1 and ?15.10 KJ mol^?1, respectively. The variables are optimized and the proposed methods are validated as per ICH guidelines. The method has been applied successfully to the estimation of losartan potassium in commercial tablets. The performance of the proposed methods was judged by calculating paired t‐ and F‐ values. The analytical results of the proposed methods when compared with those of the reference method show no significant difference in accuracy and precision and have acceptable bias.     

Synthesis,physicochemical characterization and biological activity of nano complexes of iron(III) of 3(2'‐hydroxyphenyl)‐5‐(4′‐substituted phenyl) pyrazolines and aspartic acid

Mixed ligand complexes of Iron(III) with aspartic acid and 3(2′‐hydroxy phenyl)‐5‐(4′‐substituted phenyl) pyrazolines of type [Fe(C₄O₄NH₆)₂(C₁₅H₁₂N₂OX)] and [Fe(C₄O₄NH₆)(C₁₅H₁₂N₂OX)₂], where (C₄O₄NH₆) = aspartate, (C₁₅H₁₂N₂OX) = deprotonated 3(2′‐hydroxyphenyl)‐5‐(4′‐substituted phenyl) pyrazolines (X = H, CH₃, OCH₃, Cl), have been synthesized. These newly synthesized derivatives have been physicochemically characterized by elemental analysis (C, H, N, Cl and Fe), magnetic moment data, thermogravimetric analysis, molar conductance, cyclic voltammetry, spectral analysis (UV–visible, IR, far IR and fast atom bombardment mass spectrometry). Scanning electron microscopy, transmission electron microscopy and X‐ray powder diffraction studies have been carried out for powdered samples, which show nanometric particles of these derivatives. Antibacterial and antifungal potential of free pyrazoline and some iron(III) complexes have been evaluated. Copyright © 2012 John Wiley & Sons, Ltd.     

[bmIm]OH: an efficient basic catalyst for the synthesis of 4H-benzo[d][1,3-]oxazin-4-one derivatives in solvent-free conditions

Reusable [bmIm]OH was found to be a highly efficient renewable homogenous catalyst for the rapid and convenient synthesis of benzoxazine-4-one derivatives from o-iodobenzoic-acid and benzonitrile at 75 °C in moderate to good yields. This methodology provides a facile and straightforward path to construct other related heterocycles in an eco-compatible fashion.     

Flow Injection Chemiluminescence Method for Nalbuphine Hydrochloride in Pharmaceutical Formulations Using Tris(2,2'-bipyridyl)ruthenium(II) Chloride-diperiodatocuprate(III) Reaction

Asensitive and selective method employing chemiluminescence(CL) coupled with flow injection(FI) is reported for nalbuphine hydrochloride(NAL) assay in pharmaceutical formulations. The enhancement effect of NAL on the CL reaction between tris(2,2'-bipyridyl)ruthenium(II) chloride-diperiodatocuprate(III) {Ru[(bpy)₃]²⁺-Cu(III) complex} in acidic medium is used as analytical measurement. The optimal conditions of the CL reaction were sulfuric acid 1.0×10^-3 mol/L, Ru[(bpy)₃]²⁺ 7.5×10^-5 mol/L, Cu(III)/Ag(III) complexes 4.0×10^-4/5.0×10^-4 mol/L, sample loop volume of 120 μL and flow rate of 2.5 mL/min. The sensitivities of the method in terms of detection(S/N=3) and quantification(S/N=10) limits are 5×10^-4 and 0.001 ppm(1 ppm=1 mg/L), respectively. The linear response of the instrument in the form of CL intensity with respect to NAL concentration is over the range 0.001-15.0 ppm(R²=0.9999) with relative standard deviation from 0.8% to 3.2% and injection throughput of 120 injection/h. The applications of the method include the quantitative analysis of NAL in pharmaceutical injection samples. Variations and the average results of the proposed method are not signi-ficantly different from the results of a reported method by applying F- and paired student t-test. The most likely CL reaction mechanism is written in accordance with spectrophotometric and CL studies.     

Medicinal Potential of Isoflavonoids: Polyphenols That May Cure Diabetes

In recent years, there is emerging evidence that isoflavonoids, either dietary or obtained from traditional medicinal plants, could play an important role as a supplementary drug in the management of type 2 diabetes mellitus (T2DM) due to their reported pronounced biological effects in relation to multiple metabolic factors associated with diabetes. Hence, in this regard, we have comprehensively reviewed the potential biological effects of isoflavonoids, particularly biochanin A, genistein, daidzein, glycitein, and formononetin on metabolic disorders and long-term complications induced by T2DM in order to understand whether they can be future candidates as a safe antidiabetic agent. Based on in-depth in vitro and in vivo studies evaluations, isoflavonoids have been found to activate gene expression through the stimulation of peroxisome proliferator-activated receptors (PPARs) (α, γ), modulate carbohydrate metabolism, regulate hyperglycemia, induce dyslipidemia, lessen insulin resistance, and modify adipocyte differentiation and tissue metabolism. Moreover, these natural compounds have also been found to attenuate oxidative stress through the oxidative signaling process and inflammatory mechanism. Hence, isoflavonoids have been envisioned to be able to prevent and slow down the progression of long-term diabetes complications including cardiovascular disease, nephropathy, neuropathy, and retinopathy. Further thoroughgoing investigations in human clinical studies are strongly recommended to obtain the optimum and specific dose and regimen required for supplementation with isoflavonoids and derivatives in diabetic patients.     

[HDBU][HSO4]-catalyzed facile synthesis of new 1,2,3-triazole-tethered 2,3-dihydroquinazolin-4[1H]-one derivatives and their DPPH radical scavenging activity

Research on Chemical Intermediates - A simple and efficient protocol has been developed for the synthesis of new1,2,3-triazole-2,3-dihydroquinazolin-4[1H]-one (DHQ) conjugates(6a?j) via...